Search - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Access content directly

Filter your results

4 Results
hal_authIdPerson_i : 759743
Image document

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Vincent Ribrag , Serge Koscielny , Jacques Bosq , Thibaut Leguay , Olivier Casasnovas , et al.
The Lancet, 2016, 387 (10036), pp.2402 - 2411. ⟨10.1016/S0140-6736(15)01317-3⟩
Journal articles inserm-01419476v1
Image document

Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075

Gaëlle Laboure , Marie-Cecile Parrens , Anjarasoa Tsaranazy , Magali Bordier , Steven Le Gouill , et al.
55th Annual Meeting and Exposition of the American-Society-of-Hematology, Dec 2013, La Nouvelle Orléans, United States. 126 (23), pp.3920, 2015
Conference poster hal-01290432v1

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Gandhi Damaj , Rémy Gressin , Krimo Bouabdallah , Guillaume Cartron , Bachra Choufi , et al.
Journal of Clinical Oncology, 2013, 31 (1), pp.104-10. ⟨10.1200/JCO.2012.43.7285⟩
Journal articles inserm-00868869v1
Image document

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Emmanuel Bachy , Roch Houot , Franck Morschhauser , Anne Sonet , Pauline Brice , et al.
Haematologica, 2013, 98 (7), pp.1107-14. ⟨10.3324/haematol.2012.082412⟩
Journal articles hal-00933219v1